This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Influenza surface antigen from cell culture vaccine inactivated

Updated 2 Feb 2023 | Influenza vaccine


Vaccine containing inactivated influenza surface antigen grown in Madin Darby Canine Kidney cell culture.

Drugs List

  • influenza virus surface antigen inactivated (cell culture) vaccine pre-filled syringe
  • Therapeutic Indications


    Influenza - prophylaxis

    Prophylaxis of influenza, especially in those who are at an increased risk of associated complications.

    Influenza vaccine will not control epidemics. Immunisation with this product is recommended for individuals over 2 years of age with the following conditions:
    Chronic respiratory disease, including asthma.
    Chronic cardiac disease.
    Chronic renal disease.
    Chronic neurological disease.
    Diabetes mellitus.
    Immunosuppression due to disease or treatment.
    Chronic liver disease.
    HIV infection (regardless of immune status).
    Asplenia or dysfunction of the spleen.
    Morbid obesity (Class III obesity).
    Pregnancy, all trimesters.
    Individuals aged over 65 years.

    Patients in nursing homes, residential homes, and other long-stay facilities should also be immunised, as well as carers where an elderly or disabled person may be at risk if the carer is ill.

    Immunisation should be considered for household contacts of immunocompromised individuals, as well as healthcare and social care workers who are directly involved in patient care.

    For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.



    One 0.5ml dose.


    Children aged 9 to 18 years
    One 0.5ml dose.

    Children aged 2 to 9 years
    One or two 0.5ml doses. If two doses are given, administer at least 4 weeks apart.


    For intramuscular injection only, the deltoid muscle is the preferred site of injection.


    Acute infection
    Children under 2 years
    Febrile disorder

    Precautions and Warnings

    Immunodeficiency syndromes

    Postpone immunisation if there is active or suspected infection
    Impaired response possible in immunocompromised patients
    Vaccine may not be effective in 100% of patients
    May contain polysorbate
    May contain trace amounts of betapropiolactone
    May contain trace amounts of cetyltrimethylammonium bromide
    Do not mix with other vaccines in the same syringe
    Do not use if solution is discoloured or particulates are apparent
    Inject other vaccines at different sites
    Record name and batch number of administered product
    Resuscitation facilities must be immediately available
    Warm to room temperature prior to use
    Follow national immunisation guidelines

    Pregnancy and Lactation


    Refer to current national guidelines.

    Seasonal influenza vaccine should be offered to pregnant women. A review of safety studies concluded that inactivated seasonal influenza vaccine can be safely and effectively administered during any trimester of pregnancy and that no study to date has demonstrated an increased risk of either maternal complications or adverse foetal outcomes associated with inactivated influenza vaccine.


    The vaccine may be used during breastfeeding.

    Side Effects

    Allergic reaction
    Anaphylactic reaction
    Decreased appetite
    Ecchymosis (injection site)
    Erythema at injection site
    Induration (injection site)
    Local pain (injection site)
    Local reaction at injection site
    Skin reactions
    Swelling (injection site)


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: January 2019.

    Reference Sources

    Summary of Product Characteristics: Cell-based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus suspension for injection in pre-filled syringe. Seqirus UK Limited. Revised September 2021.

    Summary of Product Characteristics: Flucelvax Tetra. Seqirus UK Limited. Revised October 2020.

    Immunisation against infectious disease - The Green Book.
    Available at
    Last accessed 23 January 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.